With a presence in Israel and major commercial hubs around the globe, we advise on inbound and outbound transactions across industries, including high-tech, life sciences, and oil and gas.
We advise public and private companies on Israel-related and international matters, as well as investment banks, government entities, private equity firms, and other investors. Our global interdisciplinary team, which also includes Israeli nationals who speak fluent Hebrew, offers multinational corporations active in Israel keen commercial and cultural insights on capital markets, M&A, regulatory, intellectual property, and venture capital matters. We work with a diverse mix of Israeli accelerators and corporations at every stage of the corporate life cycle, providing access to an international network of investor relationships, and sophisticated counsel that draws on one of the world’s largest private equity practices, trailblazing IPO experience, and a formidable track record in high-stakes M&A.
Latham also helps Israeli clients commercialize and export technologies in compliance with international regulations — unlocking their full business potential. We help clients untangle the nuances of international regulations with practical, industry-savvy guidance and trial skills. Latham draws on significant experience advising Israeli life sciences companies on clinical trial strategy and compliance, US Center for Medicare and Medicaid Services (CMS) (coverage, coding, and payment), US Federal Drug Administration (FDA), US fraud and abuse compliance, US Health Insurance Portability and Accountability Act (HIPAA), and European data privacy protection.